Investing Profile

Michael Anstey

InvestorVC
Partner at Cambridge Innovation Capital
cic.vc/team/Cambridge, United Kingdom
Photo of Michael Anstey, Partner at Cambridge Innovation Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Boston Consulting Group (BCG) Network
288 CONNECTIONS
University of Oxford Network
267 CONNECTIONS
Queen's University Network
58 CONNECTIONS
cb
$600K - $6.0M
$3.3M
4
£225M
CompanyStageDateRound SizeTotal Raised
TRIMTECH Therapeutics
SeedJun 2026$14M
SeedMar 2025$31M
$45M
Co-investors: Hakan Goker (MDC Ventures (formerly KBS Ventures)), Jeffrey Moore (MP Healthcare Venture Management), Laurence Barker (SV Health Investors' Dementia Discovery Fund (DDF))
Immutrin
Series AMar 2026$87M
$87M
Co-investors: Nihal Sinha (F-Prime Capital Partners), James N. Topper (Xelas Consulting LLC)
PredictImmune
Series BJul 2019$12M
$25M
Co-investors: Alastair Kilgour (Parkwalk Advisors)
Investment Analyst Oxford CapitalPresent
Principal Boston Consulting Group (BCG)Present
Board Member Bicycle TherapeuticsPresent
Board Member STORM Therapeutics LimitedPresent
Board Member CongenicaPresent
Board Member Proteorex Therapeutics Inc.Present
Board Member EpitopeaPresent
Board Member Innovate CambridgePresent
Board Member ImmutrinPresent
Board Observer NucleraPresent
Member Board of Directors TRIMTECH Therapeutics LimitedPresent
Co-Founder Proteorex Therapeutics Inc.Present
Partner Cambridge Innovation CapitalPresent
Queen's University First Class BSc(Hons) Biology
University of Oxford DPhil Department of Zoology